Compass Therapeutics, Inc. (CMPX) Stock

Compass Therapeutics, Inc. (CMPX) is a Healthcare stock trading at $2.03 (as of 2026-06-18), with a market capitalization of $428.61M and a trailing P/E of -5.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. It develops antibody-based therapeutics, including clinical candidates such as bispecific antibodies targeting Delta-like ligand 4/Notch and VEGF-A signaling, CD137, and PD-1/PD-L1, to treat human diseases.

Valuation — source: SEC EDGAR (first-party)
Price	$2.03
Market Cap	$428.61M
P/E Ratio	-5.4
EV / EBITDA	-4.1
Price / Book	1.96
DCF Value (model)	$-4.47
DCF Upside vs Price	-320.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-36.6%
Current Ratio	19.04
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	16.7%
FCF Growth (YoY)	9.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	6.85 (safe)

Valuation vs Sector & Industry
Stock P/E	-5.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-125.6%
vs Industry	-131.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	TANG CAPITAL MANAGEMENT LLC ($88.82M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Thomas J. Schuetz
Employees	35
Country	US
IPO Date	2021-04-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.